IN THE CLAIMS

1. (Currently Amended) A method of treating a cognitive memory dysfunction in a mammal, said method comprising administering to said mammal a pharmaceutically acceptable composition consisting essentially of a capsule or a tablet of a memory enhancing effective amount of *gugulipid,* starch, microcrystalline cellulose at a yield of 45-60%,

wherein said *gugulipid* is administered at a dosage level equivalent to 40 mg/kg/day for 7 days.

2-5. (Canceled)

6. (Currently Amended) The method of Claim 1, wherein the ~~solid dosage in the form of~~ tablet is obtained by dissolving *gugulipid* with ethanol solvent and adding starch and microcrystalline cellulose, evaporating the solvent, passing the material through 40 mesh size sieve to get the granules and compressing the granules to obtain tablets[[,]].

7. (Previously Presented) The method of Claim 1, wherein the *gugulipid* is used for treating patients suffering from human memory dysfunctions caused by Alzheimer's disease or Korsakoff's disease, alone or in combination with other treatments.

8. (Previously Presented) The method of Claim 1, wherein said dysfunction is an anticholinergic-induced amnesia.

9. (Canceled)

10. (Previously Presented) The method of Claim 8, wherein the *gugulipid* is administered as extract or solid dosage.

11-30. (Canceled)